Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupropion XL for Prevention of Seasonal Affective Disorder
NCT00046241Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2002
- Primary completion
- Jun 2003
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Seasonal Affective Disorder (SAD) comparing Bupropion XL with Placebo (2 arms). Primary endpoints: Time between randomization and onset of a seasonal depressive episode at 7 months and Proportion of depression-free subjects at 7 months. Started Sep 2002; status: completed.
02
Drugs
bupropion
03
Conditions
Seasonal Affective Disorder (SAD)
Beyond the preview
Go deeper on NCT00046241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00046241.